ALFA Finder| Value | ₹53.57 Cr |
|---|
BSE filing, NSE: MEDICAMEQ. Summary written from the filing by ALFA Finder's alert engine.
Medicamen Biotech Ltd: key numbers
- Share price
- ₹275.45
- Market cap
- ₹387.4 Cr
- Revenue (annual)
- ₹197.8 Cr
- Net profit (annual)
- ₹9.64 Cr
- P/E (TTM)
- 35.8×Sector 43.8×
- Promoter holding
- 42.57%+2.11% QoQ
- FII holding
- 4.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medicamen Biotech Ltd
All →Medicamen Biotech Board Meeting Date
Medicamen Biotech will meet on 13 Nov 2026 to consider half-yearly results for September 2026. Trading window stays closed from 01 Oct to 16 Nov 2026.
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 50 lakh equity shares at ₹530 per share under its preferential issue. The allotment raises ₹265 Crore in fresh equity capital.
- Value
- ₹265.0 Cr
Medicamen Biotech Preferential Issue
Medicamen Biotech allotted 5,00,000 equity shares at ₹530 each in a preferential issue to one investor. The allotment raised ₹26.5 Crore, taking paid-up capital to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Convertible Warrants
Medicamen Biotech allotted 5,00,000 equity shares to Shivalik Rasayan Ltd via warrant conversion at ₹530 each, raising ₹26.5 Crore. Paid-up capital rises to ₹14.06 Crore.
- Value
- ₹26.50 Cr
Medicamen Biotech Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended 30 September 2026.
Medicamen Biotech Other Announcement
Medicamen Biotech Limited's Director Sanjay Bansal sold 32,813 shares on the open market, as per a regulatory filing.
- Value
- ₹1.05 Cr
Other fund raise announcements
All →Om Metallogic Fund Raise
Om Metallogic Ltd intimated a board meeting on 14 November 2026 to approve rights issue issue price, entitlement ratio, record date and issue dates. The rights issue follows BSE in-principle approval.
Virinchi Fund Raise of ₹30 Cr
Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.
- Value
- ₹30.00 Cr
- Execution
- Warrant tenure not exceeding 18 months from allotment
IIFL Finance Fund Raise of ₹6,414 Cr
IIFL Finance's board approved a preferential issue of convertible preference shares and warrants worth Rs.6,414.20 Crore. Shareholder approval is needed at a 4 December EGM.
- Value
- ₹6,414 Cr
Bajaj Finance Fund Raise of ₹5,800 Cr
Bajaj Finance's special committee approved issuing 5.74 crore warrants to promoter Bajaj Finserv at ₹1,010 each. The issue raises about ₹5,800 crore.
- Value
- ₹5,800 Cr
Cholamandalam Investment & Finance Company Fund Raise of ₹5,000 Cr
Cholamandalam Investment sent shareholders a postal ballot notice seeking approval for a Rs 5,000 crore QIP. E-voting runs November 10 to December 9, 2026.
- Value
- ₹5,000 Cr
- Execution
- Allotment to be completed within 365 days of shareholder approval
HB Leasing & Finance Co Fund Raise
HB Leasing's board discussed fund-raising options on November 9, 2026, including equity and preference shares. No quantum or pricing is decided; advisers will be consulted.